Fundamental analysis by بورس24 | Bourse24 about Stock دجابر on 5/25/2023

Currently, the annual general meeting of Jaber Ibn Hayan Pharmaceutical Company began on Thursday (June 4), with more than 5 % of #Dojabar's shareholders. Jaber Ibn Hayan Pharmaceutical Company offers 5 product groups, including tablets and capsules, syrups, vials, spray and ointment. Currently, tablets and capsules are the highest sales among the products produced by #Dajabar. The last Jabraben Hayan Pharmaceutical capital increased in the financial year of 1399. Accordingly, the increase in the company's capital from 113 billion tomans to 226 billion tomans from the accumulated profit was registered in the corporate registration authority. In the oral penicillin line #Djaber, the complete reconstruction of the edible suspension was carried out, and the company could supply more than one million amoxicillin suspensions to the country's pharmaceutical market during the antibiotic deficiency period. Dajaber's released financial statements show that the operational revenues led to December 30, 1401 reached 561 billion tomans, up 37 percent from the same period last year. Jaber Ibn Hayan Pharmaceutical Company currently has 175 active licenses, of which 52 have been produced this year. In the 1402 budget of the company, the production of antibiotics vials is more than 50 million, which shows a 4 -fold increase compared to 1401 production. On the other hand, the cost of the company has increased and the company's sales, administrative and public costs increased. #Dajaber was able to raise its revenue to 2 billion tomans last year. Sale of April 1 #Dajaber exceeded 2 billion tomans. @Bourse24ir